Latanoprost-associated cystoid macular edema

American Journal of Ophthalmology

Volumn 126, Issue 1, 1998, Pages 134-135

  Callanan, David ^a   Fellman, Ronald L ^a   Savage, James A ^a  

^a Ophthalmic Partners of Texas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; KETOROLAC; LATANOPROST;

AGED; ARTICLE; CASE REPORT; CONJUNCTIVITIS; FEMALE; GLAUCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPIGMENTATION; HYPERTRICHOSIS; KERATOPATHY; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; RETINA MACULA EDEMA; VISUAL ACUITY;

EID: 0031821172     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(98)00082-8     Document Type: Article

References (5)

1. Alm A., Camras C.B., Watson P.G. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 41:(2suppl):1997;S105-S110.
2. Drake M.V. New medical therapies for glaucoma. Int Ophthalmol Clin. 36:1996;53-60.
3. Patel S.S., Spencer C.M. Latanoprost a review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension . Drugs Aging. 9:1996;363-378.
4. Johnstone M.A. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 124:1997;544-547.
5. Bazan N.G., Allan G. Signal transduction and gene expression in the eye a contemporary view of the pro-inflammatory, anti-inflammatory and modulatory roles of prostaglandins and other bioactive lipids . Surv Ophthalmol. 41:(2suppl):1997;S23-S34.